Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Group Incompatibility | 3 | 2016 | 11 | 1.120 |
Why?
|
| ABO Blood-Group System | 3 | 2016 | 19 | 1.110 |
Why?
|
| Kidney Transplantation | 3 | 2016 | 353 | 0.970 |
Why?
|
| Erythrocytes | 3 | 2017 | 45 | 0.940 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2020 | 7 | 0.750 |
Why?
|
| Blood Preservation | 2 | 2017 | 9 | 0.620 |
Why?
|
| Medical Waste | 1 | 2017 | 2 | 0.610 |
Why?
|
| Cold Temperature | 1 | 2017 | 40 | 0.600 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2015 | 4 | 0.510 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 9 | 0.510 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 10 | 0.510 |
Why?
|
| Erythrocyte Transfusion | 5 | 2020 | 32 | 0.500 |
Why?
|
| Autoantibodies | 1 | 2015 | 42 | 0.500 |
Why?
|
| HLA Antigens | 1 | 2014 | 35 | 0.470 |
Why?
|
| Cryopreservation | 2 | 2010 | 54 | 0.430 |
Why?
|
| Hypersensitivity | 2 | 2008 | 25 | 0.380 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2010 | 83 | 0.380 |
Why?
|
| Fever | 2 | 2008 | 56 | 0.370 |
Why?
|
| Troponin | 2 | 2020 | 82 | 0.350 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 522 | 0.340 |
Why?
|
| Immunization | 1 | 2009 | 28 | 0.340 |
Why?
|
| Autoimmunity | 1 | 2009 | 26 | 0.340 |
Why?
|
| Diphenhydramine | 1 | 2008 | 3 | 0.330 |
Why?
|
| Histamine H1 Antagonists | 1 | 2008 | 9 | 0.330 |
Why?
|
| Premedication | 1 | 2008 | 10 | 0.330 |
Why?
|
| Acetaminophen | 1 | 2008 | 18 | 0.320 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 71 | 0.310 |
Why?
|
| Humans | 17 | 2020 | 29453 | 0.300 |
Why?
|
| Adult | 8 | 2020 | 8513 | 0.280 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 6 | 0.270 |
Why?
|
| Isoantibodies | 1 | 2005 | 10 | 0.270 |
Why?
|
| Blood Donors | 2 | 2003 | 12 | 0.250 |
Why?
|
| von Willebrand Diseases | 1 | 2003 | 1 | 0.240 |
Why?
|
| Blood Component Removal | 1 | 2003 | 2 | 0.240 |
Why?
|
| Fibrinogen | 1 | 2003 | 42 | 0.230 |
Why?
|
| Diabetic Nephropathies | 1 | 2005 | 195 | 0.230 |
Why?
|
| Factor VIII | 1 | 2003 | 22 | 0.230 |
Why?
|
| Disease Transmission, Infectious | 1 | 2003 | 14 | 0.230 |
Why?
|
| Male | 9 | 2020 | 17970 | 0.220 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 2016 | 9 | 0.210 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 16 | 0.190 |
Why?
|
| Ambulances | 1 | 2020 | 12 | 0.180 |
Why?
|
| Transportation of Patients | 1 | 2020 | 21 | 0.180 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 158 | 0.160 |
Why?
|
| Blood Banks | 1 | 2017 | 6 | 0.150 |
Why?
|
| Hospitals | 1 | 2017 | 89 | 0.140 |
Why?
|
| Platelet Transfusion | 2 | 2008 | 16 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 424 | 0.140 |
Why?
|
| Time Factors | 5 | 2020 | 2013 | 0.140 |
Why?
|
| Middle Aged | 6 | 2020 | 10920 | 0.140 |
Why?
|
| Hemorrhage | 2 | 2008 | 94 | 0.130 |
Why?
|
| Female | 7 | 2020 | 18342 | 0.130 |
Why?
|
| Cryoglobulins | 1 | 2015 | 5 | 0.130 |
Why?
|
| Tissue Donors | 1 | 2016 | 167 | 0.130 |
Why?
|
| DNA, Viral | 1 | 2015 | 47 | 0.130 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 105 | 0.120 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 15 | 0.120 |
Why?
|
| Brain Death | 1 | 2014 | 27 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2014 | 3123 | 0.120 |
Why?
|
| Graft Rejection | 1 | 2014 | 149 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1057 | 0.110 |
Why?
|
| Aged | 3 | 2020 | 9572 | 0.100 |
Why?
|
| Iron Overload | 1 | 2009 | 37 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2020 | 2041 | 0.090 |
Why?
|
| Leukemia | 1 | 2009 | 37 | 0.090 |
Why?
|
| Iron | 1 | 2009 | 113 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2009 | 64 | 0.080 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2008 | 2 | 0.080 |
Why?
|
| Blood Component Transfusion | 1 | 2008 | 10 | 0.080 |
Why?
|
| Plasma | 1 | 2008 | 15 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 247 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 203 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 273 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2008 | 507 | 0.070 |
Why?
|
| Leukapheresis | 2 | 2004 | 2 | 0.070 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2005 | 2 | 0.070 |
Why?
|
| Glycosuria, Renal | 1 | 2005 | 3 | 0.070 |
Why?
|
| Hemolysis | 1 | 2005 | 12 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 251 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2005 | 113 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2005 | 55 | 0.070 |
Why?
|
| Risk Factors | 2 | 2020 | 3598 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2003 | 604 | 0.060 |
Why?
|
| Circumcision, Male | 1 | 2003 | 4 | 0.060 |
Why?
|
| Parasitic Diseases | 1 | 2003 | 5 | 0.060 |
Why?
|
| Blood-Borne Pathogens | 1 | 2003 | 7 | 0.060 |
Why?
|
| Fathers | 1 | 2003 | 11 | 0.060 |
Why?
|
| Plasma Exchange | 1 | 2003 | 10 | 0.060 |
Why?
|
| Virus Diseases | 1 | 2003 | 19 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2003 | 42 | 0.060 |
Why?
|
| Neoplasms | 1 | 2008 | 621 | 0.050 |
Why?
|
| Stem Cell Factor | 1 | 2001 | 13 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 21 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2001 | 50 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2001 | 95 | 0.050 |
Why?
|
| Cell Separation | 1 | 2001 | 87 | 0.050 |
Why?
|
| Adolescent | 1 | 2008 | 3278 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 33 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2001 | 323 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 864 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 533 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2009 | 440 | 0.040 |
Why?
|
| Mice | 1 | 2001 | 2383 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 1328 | 0.030 |
Why?
|
| Cell Division | 2 | 2001 | 97 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 2009 | 6 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2009 | 22 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2008 | 3135 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2008 | 88 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 638 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 287 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 1369 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2001 | 6 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2001 | 12 | 0.010 |
Why?
|
| E-Selectin | 1 | 2001 | 20 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2001 | 24 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 47 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 1126 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2001 | 93 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2001 | 145 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 713 | 0.010 |
Why?
|
| Animals | 1 | 2001 | 7328 | 0.010 |
Why?
|